Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs

• Published in: Cancer science Vol. 113; no. 7; pp. 2224 - 2231
• Main Authors: Milano, Gérard, Innocenti, Federico, Minami, Hironobu
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.07.2022; John Wiley and Sons Inc
• Subjects: 5-Fluorouracil; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian people; Biliary tract; Brain tumors; Cancer therapies; Carboxylesterase; carcinoma; chemotherapy; Clinical Trials, Phase III as Topic; Colorectal cancer; Cytochrome; Cytochrome P450; Cytotoxicity; Diarrhea; drug delivery system; Drug dosages; Enzymes; Fluorouracil; Gemcitabine; Genotype & phenotype; Humans; Irinotecan; Irinotecan - therapeutic use; Leucovorin - therapeutic use; liposome; Liposomes; Lung cancer; Metabolism; Metabolites; Metastases; Metastasis; Neutropenia; Pancreatic cancer; pancreatic ductal; Pancreatic Neoplasms; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; Patients; Permeability; Pharmacokinetics; Plasma; Polymorphism; Randomized Controlled Trials as Topic; Review; Tumors; United States > US; Taiwan; irinotecan; drug delivery system; carcinoma; pancreatic ductal; chemotherapy; liposome

Irinotecan is a topoisomerase inhibitor, widely used in treatment of malignancies including pancreatic ductal adenocarcinoma (PDAC) as part of the FOLFIRINOX regimen prescribed as a first‐line treatment in several countries. However, irinotecan has not been successfully introduced as a second‐line t...